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Background: Dopamine D2/3 receptor (D2/3R) agonist radiopharmaceuticals are considered superior to antagonists
to detect dopamine release, e.g. induced by amphetamines. Agonists bind preferentially to the high-affinity state of
the dopamine D2R, which has been proposed as the reason why agonists are more sensitive to detect dopamine
release than antagonist radiopharmaceuticals, but this theory has been challenged. Interestingly, not all agonists
similarly activate the classic cyclic adenosine mono phosphate (cAMP) and the β-arrestin-2 pathway, some stimulate
preferentially one of these pathways; a phenomenon called biased agonism. Because these pathways can be
affected separately by pathologies or drugs (including dopamine releasers), it is important to know how agonist
radiotracers act on these pathways. Therefore, we characterized the intracellular signalling of the well-known
D2/3R agonist radiopharmaceuticals NPA and PHNO and of several novel D2/3R agonists.
Methods: cAMP accumulation and β-arrestin-2 recruitment were measured on cells expressing human D2R.
Results: All tested agonists showed (almost) full agonism in both pathways.
Conclusions: The tested D2/3R agonist radiopharmaceuticals did not exhibit biased agonism in vitro.
Consequently, it is likely that drugs (including psychostimulants like amphetamines) and/or pathologies that
influence the cAMP and/or the β-arrestin-2 pathway may influence the binding of these radiopharmaceuticals.
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The dopamine (DA) system plays a central role in several
neuropsychiatric disorders including Parkinson's disease
and schizophrenia. DA D2 receptor (D2R) antagonists are
used to reduce psychotic symptoms, whereas D2R agonists
are commonly used in the treatment of Parkinson's dis-
ease. Consequently, radiopharmaceuticals targeting D2Rs
are of value to obtain insight in the pathophysiology of
these brain disorders.
The D2R is a subfamily within the superfamily of G-
protein-coupled receptors (GPCRs) and contains several
subtypes including some in the D2-like subfamily, the D2
(splice variants D2short (D2S) and D2long (D2L) [1]), D3
and D4 receptors [2]. They primarily couple to the Gi/o
type of G-proteins to inhibit the enzyme adenylyl cyclase
in producing cyclic adenosine mono phosphate (cAMP)
[2]. Like other GPCRs, they exhibit interconvertible* Correspondence: j.vanwieringen@amc.uva.nl
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reproduction in any medium, provided the orighigh- and low-affinity states for agonists in vitro [3]. In
the high-affinity state, the receptor is coupled to the G-
protein and this is considered to be the active state of
the receptor. In the low-affinity state, the receptor is
uncoupled and consequently inactive.
Dopamine D2/3 receptor (D2/3R) agonist radiopharma-
ceuticals for positron emission tomography (PET) have
been developed successfully (e.g. 11C-NPA (N-propylnor-
apomorphine) and 11C-PHNO ((+)-4-propyl-9-hydroxy-
naphthoxazine)), and such agonists are more sensitive in
detecting DA release in humans compared to antago-
nists like 11C-raclopride [4-7]. It has been proposed that
the reason for this increased sensitivity may be that D2/3R
agonist radiopharmaceuticals bind preferentially to the
high-affinity state of the dopamine D2R, whereas antago-
nists do not differentiate between the high- and low-
affinity states [8-10]. However, this proposal depends upon
the existence of two affinity states in vivo and the results
of recent studies challenged this theory [11-13].This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited.
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thought to signal intracellularly only through their G-
proteins. However, it was shown recently that besides
this (canonical) pathway, DA receptors can also exert ef-
fects through proteins of which it was initially thought
that they regulate receptor desensitization (non-canonical
pathway, Figure 1). This cAMP-independent mechanism
involves the adaptor protein β-arrestin-2. Compounds can
have distinct patterns of responses on these pathways; this
phenomenon is called ‘biased agonism’ or ‘ligand-directed
signalling’ [14,15].
Activation of the β-arrestin-2 pathway may play a role
in the increased sensitivity to detect dopamine release
in vivo. Activation of this pathway eventually leads to
the regulation of glycogen synthase kinase 3 (GSK3), a
protein that is involved in many DA-dependent behav-
iours [16]. Many drugs (antipsychotics, antidepressants,
lithium) affect this cascade, and recently compounds,
based on the aripiprazole scaffold, were discovered that
are functionally selective for the β-arrestin-2 pathway
[17,18]. Consequently, it is important to characterize
pharmacologically the intracellular pathways that DAFigure 1 Canonical (G-protein-dependent) and non-canonical (G-prote
resulting in increased activation of GSK3. D2R, dopamine D2 receptor; AC, a
kinase A; Akt, protein kinase B; GSK3, glycogen synthase kinase 3.D2/3R agonist radiopharmaceuticals act on. This infor-
mation is not only relevant when the radiopharmaceuti-
cals are used to evaluate actions of novel drugs which
may show biased agonism but also because β-arrestin-2
itself may be involved in the desensitization of DA re-
ceptors and as such in the detection of DA. Literature
about biased signalling of currently available agonist
PET radiotracers 11C-NPA and 11C-PHNO at cloned DA
receptors does not exist, and therefore, we tested un-
labelled (‘cold’) NPA and PHNO for agonism in both the
cAMP and β-arrestin-2 assays.
Additionally, and in a broader perspective, we are de-
veloping new DA D2/3R agonist radiotracers for PET and
single-photon emission computed tomography (SPECT)
imaging, where the investigated compounds are based
on the 2-aminomethylchromane (AMC) scaffold. We
have tested agonism for our AMC compounds by means
of a cAMP assay and have found that most of these
compounds showed full agonism for this canonical path-
way [19]. As for NPA and PHNO, also for these new
AMC tracers, we were interested to evaluate if they would
show biased agonism. Finally, the D2/3R antagonist SPECTin-independent) signalling of D2R. Beta-arrestin-2 inactivates Akt
denylyl cyclase; cAMP, cyclic adenosine mono phosphate; PKA, protein
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studies including studies on Parkinsonism [20] and on
amphetamine-induced DA release [21]. Based on early
studies in rats showing that IBZM was a potent inhibitor
of an apomorphine-induced syndrome (apomorphine is a
D2R agonist) of hyperactivity and stereotypy, it was con-
cluded that IBZM was a DA antagonist [22]. As no other
research examining the functional agonism or antagonism
of IBZM has been reported, we also tested IBZM for
biased agonism. Of note, studies with other receptors
show that antagonists for one signalling pathway of a re-
ceptor may be agonists for another pathway.
Accordingly, in this study, we have tested if clinically
used as well as recently developed D2/3R radiopharma-
ceuticals show biased agonism.
Methods
The agonists R(-)-propylnorapomorphine HCl, pergolide
mesylate and DA HCl were obtained from Sigma-
Aldrich (Zwijndrecht, The Netherlands). (+)PHNO HCl
was obtained from Axon Medchem (Groningen, The
Netherlands). The cold-labelled (i.e. iodine-127-labelled)
antagonist iodo-6-methoxybenzamide (IBZM) was a
kind gift of GE Healthcare (Eindhoven, The Netherlands).
We have previously presented the synthesis and evalu-
ation of a new group of cold-labelled D2/3R agonist tracers
based on an AMC scaffold, including (R)N-[7-hydroxy-
chroman-2-yl]-methyl 4-iodobenzyl amine (codenamed 11a),
(R)-2-[(4-(4-fluorobutoxy)benzylamino)methyl] chroman-
7-ol (codenamed 12a) and (R)-1-(4-(2-fluoroethoxy)phenyl)-
4-(4-(7-hydroxychroman-2-yl)-3-azabutyl)-piperazine
(codenamed 12d) [19] (see Figure 2).
cAMP accumulation assay and receptor binding assay
As described in detail earlier [19], cAMP accumulation
was measured in HEK 293 cells stably expressing the hu-
man DA D2L receptor with an assay from PerkinElmerFigure 2 The tested compounds. The cold analogues of the clinically ap
AMC compounds 11a, 12a and 12d (published in [19]).(Waltham USA). Receptor binding experiments were
done on the membranes obtained from the above men-
tioned cells using 3H-spiperone as radioligand.
β-arrestin-2 recruitment assay
The PathHunter™ eXpress human DA receptor D2L
CHO-K1 β-arrestin-2 GPCR assay from DiscoveRx
(Fremont, CA, USA) was used according to the manu-
facturer's protocol. Cells were seeded at a density of
8,000 cells/well in a 96-well plate in 100 μl Path-
Hunter™ CP reagent and incubated 48 h in a humidified
atmosphere at 5% CO2 at 37°C. After 48 h, the com-
pounds dissolved in Hank's balanced salt solution
supplemented with 5 mM HEPES and 1.1% DMSO
were added to the wells in duplo. Then a detection
mixture was made and added to the wells. The cells
were incubated for 60 min at room temperature, and
subsequently chemiluminescence was measured on a
Wallac Victor (PerkinElmer, Zaventum, Belgium).
Results
cAMP
In our previous studies the novel AMC compounds 11a,
12a and 12d bound with a high-affinity to the DA D2-
high receptor and were full agonists compared to DA it-
self; DA, 11a and 12a were similarly potent, and 12d was
a little more potent [19]. NPA and PHNO were also full
agonists, displaying Emax values even higher than those
of DA that was set at 100% efficacy as a reference. Fur-
thermore, NPA and PHNO were, respectively, 1 log and
2 log units more potent than DA. The SPECT tracer
IBZM was an inverse agonist. All data are compiled in
Table 1.
β-arrestin-2
NPA, PHNO, 11a, 12a and 12d demonstrated full agon-
ism for this pathway (using DA as the 100% reference),plied tracers NPA, PHNO and IBZM and from the developed series of
Table 1 Radioligand binding and functional activities of different compounds*
cAMP β-arrestin-2
Compound pKi D2-high Potency Efficacy Potency Efficacy
pEC50 % pEC50 %
Dopamine 6.97† 9.22† 100† 6.97 100
NPA 10.13† 10.31 118 9.67 103
PHNO 9.47† 11.03 114 9.39 99
11a 8.69† 9.16† 86† 8.26 81
12a 8.26† 9.42† 96† 8.36 88
12d 8.30† 9.82† 94† 8.61 88
IBZM 6.99‡ 9.08 Inverse agonist - Neutral antagonist
*pKi, pEC50 and Emax values are the average of at least two duplicate experiments with standard deviations (SD) values that were less than a third of the mean.
†Parts published earlier in van Wieringen et al, 2014 [19].
‡For IBZM no high-affinity state was detected; pKi value represents affinity for the total number of D2 receptors.
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the β-arrestin-2 pathway, all tested compounds had
higher potencies than DA (pEC50 of 6.97) with NPA be-
ing the most potent (pEC50 of 9.67). See Figure 3 and
Table 1 for all data.
The potencies of all tested compounds, as measured in
the two functional tests, correlated (r =0.80; Spearman's
rank correlation).
Discussion
We found that all agonist compounds tested that were
active in the cAMP assays were also active in β-arrestin-











































Figure 3 Concentration response curves of different compounds
for arrestin signalling. Quantitative analysis of the data is shown
in Table 1.Moreover, the potencies of all agonists in the two func-
tional assays were well correlated with a slope close to
unity (1.046 ± 0.3965). However, their potency was con-
sistently higher in the cAMP than in the β-arrestin-2
assay, especially for DA and PHNO. This may be ex-
plained by the presence of a receptor reserve in the cells
used in the cAMP experiments causing signal amplifica-
tion while the arrestin recruitment assay measures a
more 1:1 interaction of the receptor to arrestin. All in
all, the present data do not support biased agonism for
these compounds.
Skinbjerg and colleagues recently demonstrated that the
striatal binding potential (BPND) of the agonist
11C-MNPA
and the antagonist (or inverse agonist; for discussion see
below) 18F-fallypride was not different in wild-type mice
and β-arrestin-2 knockout mice [23]. The results of this
study suggest that a modified arrestin pathway does not
affect radiotracer binding during ‘baseline’ conditions, in-
dependent of agonist signalling properties of the radio-
tracer. A modification in the arrestin pathway is more
likely to be demonstrated using a pharmacological chal-
lenge, as shown in the amphetamine studies by Skinbjerg
and co-workers [23]. The current work, therefore, appears
most relevant to drug interaction studies, and conse-
quently may shed new light on the reason why agonist
D2/3R radiopharmaceuticals are more sensitive to detect
DA release than antagonists [4-7]. More specifically, it has
been demonstrated that arrestin desensitizes the D2R and
prepares it for internalization by hindering the coupling of
the G-protein to the receptor. Consequently, the desensi-
tized receptor is in the low-affinity state [24]. So, after
agonist binding, the receptor is switched to the low-
affinity state and kept in that state by arrestin; thus, theor-
etically the density of D2 receptors in the high-affinity
state decreases after binding with an agonist that recruits
arrestin.
DA release is measured with PET or SPECT by asses-
sing the difference in binding potential for radiotracers
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compared to a baseline condition [8,21,25]. DA can dis-
place the radiotracer from the receptor (competition
model), but the lower binding potential after a DA chal-
lenge may also be explained partly by internalization of
DA D2/3Rs. In a typical PET/SPECT study, DA release is
measured 1 h after a DA challenge [8,21], and internaliza-
tion of DA D2/3Rs has been reported in a
11C-raclopride
PET study in cats already 1 h after the administration of
the DA releaser amphetamine [26]. Moreover, Guo and
co-workers [27] demonstrated a lower binding affinity of
agonist and antagonists radiotracers for internalized DA
D2/3Rs, possibly reflecting a poorer accessibility than to
surface receptors. Since, the β-arrestin pathway plays an
important role in the internalization of DA D2/3Rs, it is
important to know if a radiotracer is biased towards or
away from β-arrestin translocation. Radiotracers that are
biased towards cAMP may not promote β-arrestin-
mediated receptor internalization and in theory may be
more accurate tools to detect DA release. Recently cAMP-
specific compounds have been developed for the dopa-
mine D2R and may offer the opportunity to be developed
further to radioligands in future investigations [28]. These
propositions may have implications for the interpretation
of results from clinical studies with agonist tracers, par-
ticularly pharmacological challenge studies, e.g. with DA-
releasing psychostimulants.
Since all tested agonists activate the cAMP as well as
the β-arrestin-2 pathway, it is likely that they will also
activate both GSK3 (via β-arrestin-2) and protein kinase
A (via cAMP). This information is of importance when
these radiopharmaceuticals are used to study or evaluate
(novel) drugs. Dopaminergic drugs, like antipsychotics,
but also drugs affecting other monoamine systems like
the serotonin releaser fenfluramine, exert actions on the
β-arrestin-2 pathway. Lithium, a drug used in the treat-
ment of bipolar disorder, was found to have a direct
inhibiting action on GSK3 [16]. Finally, compounds
based on the aripiprazole scaffold were recently discov-
ered that are functionally selective for the β-arrestin-2
pathway and that show robust antipsychotic effects in
rodents [17,18]. So, it is likely that drugs that influence
the canonical and/or the non-canonical pathway, may
influence indirectly the in vivo binding of our presently
tested D2/3R agonists, including the radiotracers
11C-
NPA and 11C-PHNO, which are frequently used in hu-
man studies [5,7].
Our novel finding that IBZM showed inverse agonism
in the cAMP assay is in line with recent findings that
the antipsychotics nemonapride and sulpiride (similar to
IBZM, benzamides), and also antipsychotics from other
chemical classes (e.g. butyrophenones like haloperidol),
that were initially believed to be DA receptor neutral an-
tagonists are now re-classified as inverse agonists by theresults of studies using functional assays [29]. It is al-
leged that inverse agonists bind preferentially to the in-
active state of the receptor [30], so this might indicate
that in vivo 123I-IBZM predominantly binds to striatal
D2Rs in their inactive low-affinity state. Since
11C-
raclopride PET and 18F-fallypride are frequently used
to assess DA release in vivo [5,7,23], it may be of rele-
vance to test whether raclopride and fallypride are also
inverse agonists for cAMP instead of antagonists. If our
proposition is true that benzamide radiopharmaceuti-
cals in vivo bind predominantly to DA D2/3Rs in their
low-affinity state, this will extend the discussion on
why benzamides tracers are less sensitive than agonists
D2/3R radiopharmaceuticals (like
11C-PHNO) to detect
DA release in vivo [5,7].
Nevertheless, more functional pharmacological charac-
terization studies on agonist and antagonist (or inverse
agonists) D2/3R radiopharmaceuticals are needed to fully
understand the mechanism how dopamine release can
be detected in vivo using such radiotracers.
In this study, we focused on the D2R. Since all devel-
oped radiopharmaceuticals to image this receptor also
bind to the D3R, it may be of interest to evaluate in fu-
ture studies also how these radiotracers act on intracel-
lular signalling of the D3R.Conclusions
The agonist compounds tested exhibited agonism for both
the cAMP and the β-arrestin-2 pathways, and no evidence
was found for biased agonism. This information is crucial
for the interpretation of findings with these tracers, espe-
cially in drug interaction studies. In addition, our data
demonstrate, for the first time, that the benzamide IBZM
is an antagonist for both β-arrestin-2 recruitment and
cAMP formation, displaying inverse agonist properties for
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